Abril - 2017

arros

-O

liveira

378

ssoc

ras

2017; 63(4):371-378

39.

Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, et al.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin

for premenopausal breast cancer (STAGE): a double-blind, randomised

phase 3 trial. Lancet Oncol. 2012; 13(4):345-52.

40.

Sestak I. Preventative therapies for healthy women at high risk of breast

cancer. Cancer Manag Res. 2014; 17(6):423-30.

41. Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer. Int J

Womens Health. 2015; 7:493-9.

42. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-

-Wende J, et al.; NCIC CTGMAP.3 Study Investigators. Exemestane for breast-

-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364(25):

2381-91.

43. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al.; IBIS-II

investigators. Anastrozole for prevention of breast cancer in high-risk

postmenopausal women (IBIS-II): an international, double-blind, randomised

placebo-controlled trial. Lancet. 2014; 383(9922):1041-8.

44.

Kubatka P, Sadlonová V, Kajo K, Nosál’ová G, Ostatníková D, Adamicová

K. Chemopreventive effects of anastrozole in a premenopausal breast cancer

model. Anticancer Res. 2008; 28(5A):2819-23.

45.

Sadlonova V, Kubatka P, Kajo K, Ostatnikova D, Nosalova G, Adamicova K,

et al. Side effects of anastrozole in the experimental pre-menopausal

mammary carcinogenesis. Neoplasma. 2009; 56(2):124-9.